Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
21
05
2020
accepted:
14
10
2020
pubmed:
20
11
2020
medline:
15
12
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
Neuroendocrine carcinoma of the cervix (NEC) is a rare and highly aggressive cervical malignancy. Given that no targeted therapy has been approved specifically to NEC, we investigated the presence of novel, potentially targetable biomarkers in a large cohort of NEC. Sixty-two NEC were molecularly profiled for biomarkers of targeted therapies including antibody-drug conjugates [delta-like canonical notch ligand 3 (DLL3), a trophoblast cell surface antigen 2 (TROP-2), and folate receptor 1 (FOLR1)], NTRK1-3 gene fusions, and immune checkpoint inhibitors [programmed death-ligand 1 (PD-L1), tumor mutational burden, and microsatellite instability] using immunohistochemistry and DNA/RNA next-generation sequencing assays. A cohort of squamous cell carcinomas of the cervix (n=599) was used for comparison for immune-oncology biomarkers. DLL3 expression was observed in 81% of the cases. DLL3 expression was inversely correlated with commonly observed pathogenic mutations in PIK3CA (17%) (P=0.018) and PTEN (10%) (P=0.006). Other more frequently seen pathogenic mutations (TP53 17%, KRAS 11%, and CTNNB1 5%) were not associated with DLL3 expression. TROP-2 expression was detected in only 1 case and no case expressed FOLR1. Although NTRK protein expression was observed in 21% of the cases, none of these had an NTRK gene fusion. PD-L1 expression (10%) and high tumor mutational burden (3%) were significantly less frequent in NEC compared with the squamous cell carcinoma cohort (79% and 11%, respectively). None of the NEC exhibited high microsatellite instability status. Despite frequent DLL3 expression in NEC, a potential therapeutic benefit of DLL3-targeted drugs remains uncertain given the recent failure of the Rova-T therapeutic trial in small cell lung carcinomas. Small cohorts of NEC enriched in PIK3CA/PTEN/AKT and programmed cell death protein 1/PD-L1 alterations indicate therapeutic roles for their respective inhibitors.
Identifiants
pubmed: 33208671
pii: 00129039-202104000-00009
doi: 10.1097/PAI.0000000000000884
pmc: PMC8132903
doi:
Substances chimiques
Biomarkers, Tumor
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-304Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
D.A., E.C., and J.S. are employees of Caris Life Sciences. The remaining authors declare no conflict of interest.
Références
Clin Breast Cancer. 2020 Aug;20(4):326-331.e1
pubmed: 32197944
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Papillomavirus Res. 2018 Jun;5:134-142
pubmed: 29555602
Cancer Med. 2018 Mar;7(3):746-756
pubmed: 29436178
Gynecol Oncol Rep. 2019 Apr 23;28:141-144
pubmed: 31080864
Mol Cancer Res. 2020 Jan;18(1):3-19
pubmed: 31659006
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966
pubmed: 31506387
Malays J Med Sci. 2019 Sep;26(5):151-157
pubmed: 31728128
Biomolecules. 2019 Apr 17;9(4):
pubmed: 30999672
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322
pubmed: 29118225
Arch Gynecol Obstet. 2019 Feb;299(2):543-549
pubmed: 30411160
Ann Oncol. 2020 Jul;31(7):861-872
pubmed: 32272210
Cancer Med. 2019 Dec;8(17):7322-7329
pubmed: 31609094
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Mod Pathol. 2019 Jan;32(1):147-153
pubmed: 30171197
JAMA Otolaryngol Head Neck Surg. 2013 Jun;139(6):617-22
pubmed: 23787421
Clin Breast Cancer. 2019 Apr;19(2):131-136
pubmed: 30268765
Gynecol Oncol. 2018 Feb;148(2):422-429
pubmed: 29248196
Oncotarget. 2018 Nov 9;9(88):35809-35812
pubmed: 30533196
BMC Cancer. 2018 May 4;18(1):530
pubmed: 29728073
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Gynecol Oncol. 2016 Dec;143(3):552-557
pubmed: 27645621
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Int J Gynecol Pathol. 2021 Jan;40(1):73-77
pubmed: 32044823
Gynecol Oncol Rep. 2014 Oct 25;10:28-9
pubmed: 26075998
Oncologist. 2020 Sep;25(9):810-817
pubmed: 32372416
Oncologist. 2017 Jun;22(6):631-637
pubmed: 28550027
Gynecol Oncol. 2016 Jun;141(3):588-591
pubmed: 27079212
Am J Surg Pathol. 2018 Jun;42(6):750-760
pubmed: 29505425
Histopathology. 2020 Jul;77(1):100-111
pubmed: 31971278
Gynecol Oncol. 2018 May;149(2):420-427
pubmed: 29458976
PLoS One. 2014 Mar 18;9(3):e92071
pubmed: 24642661
Gynecol Oncol. 2017 Mar;144(3):637-646
pubmed: 28057354
Eur J Cancer. 2018 May;94:179-186
pubmed: 29571084
Lung Cancer. 2019 Sep;135:73-79
pubmed: 31447005
Appl Immunohistochem Mol Morphol. 2020 Oct;28(9):661-668
pubmed: 31517642
Gynecol Oncol Res Pract. 2017 Feb 2;4:3
pubmed: 28174665
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254